REC-3964 for C. difficile Infection
(ALDER Trial)
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. However, if you are taking medications for chronic diarrheal illnesses like ulcerative colitis or Crohn's disease, they must be controlled to participate.
What data supports the effectiveness of the drug REC-3964 for C. difficile Infection?
The research on bezlotoxumab, a drug used for recurrent C. difficile infections, shows it significantly reduces recurrence compared to a placebo, which suggests that similar treatments might be effective. Additionally, novel biomarkers and PCR cycle thresholds have been identified as important predictors for recurrence, indicating that understanding these factors can help in optimizing treatment strategies.12345
What is the purpose of this trial?
This is a multi-center, open-label study to investigate the safety, tolerability, pharmacokinetics (PK) and efficacy of RE-3964 (doses of either 250 mg or 500 mg PO every 12 hours) for the reduction of Clostridioides difficile infection (CDI).
Eligibility Criteria
This trial is for adults over 18 who have had diarrhea due to Clostridioides difficile infection (CDI), confirmed by a stool test, and were treated with vancomycin. Participants should be at high risk of the infection coming back after treatment and must join within two days of finishing their vancomycin course.Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive REC-3964 (250 mg or 500 mg) or undergo observation for 28 days
Follow-up
Participants are monitored for safety and effectiveness after treatment
Extended Follow-up
Participants are monitored for recurrent Clostridioides difficile infection (rCDI) and adverse events
Treatment Details
Interventions
- REC-3964
Find a Clinic Near You
Who Is Running the Clinical Trial?
Recursion Pharmaceuticals Inc.
Lead Sponsor